Improvement of anticoagulant treatment using a dynamic decision support algorithm: a Danish Cohort study
Related Experiment Video
Updated: May 3, 2026

In Vitro Thrombosis Test for Ventricular Assist Devices
Published on: March 21, 2025
Peter Brønnum Nielsen1, Søren Lundbye-Christensen2, Lars Hvilsted Rasmussen1
1Thrombosis Research Unit, Aalborg University, Aalborg, Denmark.
Introduction:
Warfarin is the most widely prescribed vitamin K antagonist and in the United States and Europe more than 10 million people are currently in long-term oral anticoagulant treatment. This study aims to retrospectively validate a dynamic statistical model providing dosage suggestions to patients in warfarin treatment.
Materials And Methods:
The model was validated on a cohort of 553 patients with a mean TTR of 83%. Patients in the cohort were self-monitoring and managed by a highly specialised anticoagulation clinic. The predictive model essentially consists of three parts handling INR history, warfarin dosage and biological noise, which allows for prediction of future INR values and optimal warfarin dose to stay on INR target. Further, the model is based on parameters initially being set to population values and gradually individualised during monitoring of patients.
Primary Outcome:
Time in therapeutic range was used as surrogate quality measure of the treatment, and model-suggested dosage of warfarin was used to assess the accuracy of the model performance.
Results:
The accuracy of the model predictions measured as median absolute error was 0.53 mg/day (interquartile range from 0.25 to 1.0). The model performance was evaluated by the difference between observed and predicted warfarin intake in the preceding week of an INR measurement. In more than 70% of the cases where INR measurements were outside the therapeutic range, the model suggested a more reasonable dose than the observed intake.
Conclusion:
Applying the proposed dosing algorithm can potentially further increase the time in INR target range beyond 83%.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Venous Thrombosis IV: Nursing Management

